CDNA

CareDx, Inc [CDNA] Stock Forecast

Q: What is CareDx, Inc stock symbol ?

CareDx, Inc is a US stock, located in South san francisco of Ca and trading under the symbol CDNA

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CDNA Stock Summary

CDNA has more than 10 years of cash runway (129 months)

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

Top 10 Correlated ETFs

CDNA

Top 10 Correlated Stocks

CDNA

In the News

CDNA Financial details

Company Rating

Neutral

Market Cap

441.67M

Income

-190.28M

Revenue

280.32M

Book val./share

4.89

Cash/share

4.41

Dividend

Dividend %

Employees

635

Optionable

Shortable

Yes

Earnings

08 May 2024

P/E

-2.39

Forward P/E

PEG

-0.16

P/S

1.58

P/B

1.74

P/C

1.86

P/FCF

-15.99

Quick Ratio

3.67

Current Ratio

4.02

Debt / Equity

0.13

LT Debt / Equity

0.11

EPS (TTM)

-3.54

EPS next Y

EPS next Q

EPS this Y

145.83%

EPS next Y

EPS next 5Y

EPS last 5Y

46.76%

Revenue last 5Y

17.15%

Revenue Q/Q

-2.42%

EPS Q/Q

413.95%

SMA20

-20%

SMA50

-11.11%

SMA100

-20%

Inst Own

83.79%

Inst Trans

0.78%

ROA

-39%

ROE

-51%

ROC

-0.26%

Gross Margin

63%

Oper. Margin

-37%

Profit Margin

-68%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

4.8-12.93

52W High

-31.67%

52W Low

+105%

RSI

Rel Volume

0.31

Avg Volume

923.04K

Volume

283.51K

Perf Week

-10.28%

Perf Month

-30.45%

Perf Quarter

64%

Perf Half Y

41.87%

Beta

1.446

Volatility

0.19%, 0.9%

Prev Close

1.61%

Price

8.2

Change

-1.2%

CDNA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	3.01	4.13	5.67	6.03	5.21
Net income per share	-0.52	-0.4	-0.59	-1.44	-3.54
Operating cash flow per share	-0.07	0.72	-0.37	-0.47	-0.34
Free cash flow per share	-0.15	0.5	-0.76	-0.93	-0.51
Cash per share	0.91	4.83	6.67	5.5	4.38
Book value per share	2.35	5.97	8.92	8.08	4.86
Tangible book value per share	0.7	4.51	7.25	6.57	3.26
Share holders equity per share	2.35	5.97	8.92	8.08	4.86
Interest debt per share	-0.02	0.4	0.41	0.8	0.64
Market cap	909.21M	3.37B	2.38B	608.4M	645.18M
Enterprise value	874M	3.25B	2.04B	557.48M	597.2M
P/E ratio	-41.39	-179.95	-77.49	-7.94	-3.39
Price to sales ratio	7.16	17.52	8.02	1.89	2.3
POCF ratio	-328.35	100.73	-123.14	-24.11	-35.09
PFCF ratio	-148.61	145.97	-60.07	-12.27	-23.35
P/B Ratio	9.18	12.13	5.1	1.41	2.47
PTB ratio	9.18	12.13	5.1	1.41	2.47
EV to sales	6.88	16.9	6.9	1.73	2.13
Enterprise value over EBITDA	-35.17	-200.31	-68.54	-7.21	-7.28
EV to operating cash flow	-315.64	97.19	-105.98	-22.09	-32.48
EV to free cash flow	-142.86	140.83	-51.7	-11.25	-21.62
Earnings yield	-0.02	-0.01	-0.01	-0.13	-0.29
Free cash flow yield	-0.01	0.01	-0.02	-0.08	-0.04
Debt to equity	0.03	0.07	0.05	0.09	0.13
Debt to assets	0.02	0.05	0.04	0.07	0.07
Net debt to EBITDA	1.42	7.31	11.1	0.66	0.58
Current ratio	2.07	3.95	5.61	5.1	4.02
Interest coverage	6.63	-65.37	0	-20.53	0
Income quality	0.13	-1.79	0.63	0.33	0.1
Dividend Yield	0	0	0	0	0
Payout ratio	-0.2	-0.07	-0.07	0	0
Sales general and administrative to revenue	0.29	0.25	0.25	0.31	0.42
Research and developement to revenue	0.24	0.25	0.26	0.28	0.29
Intangibles to total assets	0.46	0.19	0.15	0.15	0.18
Capex to operating cash flow	1.21	-0.31	1.05	0.96	0.5
Capex to revenue	-0.03	-0.05	-0.07	-0.08	-0.03
Capex to depreciation	-0.61	-1.09	-1.7	-1.52	-0.47
Stock based compensation to revenue	0.18	0.12	0.12	0.14	0.18
Graham number	5.25	7.36	10.85	16.16	19.67
ROIC	-0.21	-0.05	-0.06	-0.15	-0.31
Return on tangible assets	-0.27	-0.06	-0.06	-0.17	-0.48
Graham Net	0.16	3.55	5.76	4.51	1.12
Working capital	37.09M	203.88M	356.06M	311.87M	235.64M
Tangible asset value	29.6M	209.47M	378.7M	350.34M	175.29M
Net current asset value	19.19M	182.27M	332.62M	275.77M	90.43M
Invested capital	0.03	0.07	0.05	0.09	0.13
Average receivables	16.91M	29.34M	47.19M	63.04M	58.69M
Average payables	5.11M	7.58M	11.5M	11.64M	11.41M
Average inventory	5.48M	8.01M	13.6M	18.21M	19.35M
Days sales outstanding	69.1	65.76	73.59	75.22	66.48
Days payables outstanding	44.21	55.82	49.99	32.34	44.98
Days of inventory on hand	48.29	57.9	64.41	62.56	68.04
Receivables turnover	5.28	5.55	4.96	4.85	5.49
Payables turnover	8.26	6.54	7.3	11.29	8.11
Inventory turnover	7.56	6.3	5.67	5.83	5.36
ROE	-0.22	-0.07	-0.07	-0.18	-0.73
Capex per share	-0.08	-0.22	-0.39	-0.46	-0.17

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.54	1.44	1.31	1.24	1.23
Net income per share	-0.34	-0.44	-0.46	-0.43	-2.21
Operating cash flow per share	0.13	0.01	-0.01	-0.19	-0.16
Free cash flow per share	0.07	-0.04	-0.05	-0.23	-0.19
Cash per share	5.48	5.33	5.25	4.95	4.41
Book value per share	8.05	7.83	7.53	7.27	4.89
Tangible book value per share	6.55	6.24	5.98	5.68	3.28
Share holders equity per share	8.05	7.83	7.53	7.27	4.89
Interest debt per share	0.76	0.7	0.68	0.65	0.64
Market cap	610.72M	490.3M	457.69M	379.25M	640.67M
Enterprise value	559.79M	447.64M	406.31M	338.48M	592.69M
P/E ratio	-8.33	-5.16	-4.59	-4.04	-1.36
Price to sales ratio	7.41	6.35	6.51	5.64	9.77
POCF ratio	85	730.7	-917.22	-37.26	-76.44
PFCF ratio	156.27	-233.48	-159.98	-29.88	-64.23
P/B Ratio	1.42	1.17	1.13	0.96	2.45
PTB ratio	1.42	1.17	1.13	0.96	2.45
EV to sales	6.79	5.79	5.78	5.04	9.04
Enterprise value over EBITDA	-29.25	-18.4	-19.39	-14.25	-28.4
EV to operating cash flow	77.91	667.13	-814.24	-33.25	-70.72
EV to free cash flow	143.24	-213.16	-142.02	-26.67	-59.42
Earnings yield	-0.03	-0.05	-0.05	-0.06	-0.18
Free cash flow yield	0.01	0	-0.01	-0.03	-0.02
Debt to equity	0.09	0.09	0.09	0.09	0.13
Debt to assets	0.07	0.07	0.07	0.07	0.07
Net debt to EBITDA	2.66	1.75	2.45	1.72	2.3
Current ratio	5.1	5.17	4.84	4.75	4.02
Interest coverage	-10.22	53.93	0	0	0
Income quality	-0.39	-0.03	0.02	0.43	0.07
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.3	0.36	0.42	0.51	0.4
Research and developement to revenue	0.29	0.32	0.29	0.28	0.28
Intangibles to total assets	0.15	0.16	0.16	0.17	0.18
Capex to operating cash flow	-0.46	-4.13	4.73	0.25	0.19
Capex to revenue	-0.04	-0.04	-0.03	-0.04	-0.02
Capex to depreciation	-0.73	-0.58	-0.47	-0.5	-0.53
Stock based compensation to revenue	0.15	0.18	0.18	0.19	0.15
Graham number	7.88	8.83	8.86	8.42	15.61
ROIC	-0.04	-0.05	-0.06	-0.06	-0.07
Return on tangible assets	-0.04	-0.05	-0.06	-0.06	-0.3
Graham Net	4.49	4.31	4.11	3.86	1.13
Working capital	311.87M	299.6M	286.32M	272.49M	235.64M
Tangible asset value	350.34M	334.77M	322.03M	307.47M	175.29M
Net current asset value	275.77M	263.23M	251.21M	238.12M	90.43M
Invested capital	0.09	0.09	0.09	0.09	0.13
Average receivables	68.37M	62.81M	55.47M	51.66M	51.38M
Average payables	10.28M	11.4M	11.37M	9.43M	10.92M
Average inventory	18.66M	18.63M	18.43M	18.41M	18.72M
Days sales outstanding	72.44	69.09	66.09	69.24	70.09
Days payables outstanding	30.34	44.58	34.35	32.91	44.13
Days of inventory on hand	58.69	62.45	65.5	65.95	66.75
Receivables turnover	1.24	1.3	1.36	1.3	1.28
Payables turnover	2.97	2.02	2.62	2.73	2.04
Inventory turnover	1.53	1.44	1.37	1.36	1.35
ROE	-0.04	-0.06	-0.06	-0.06	-0.45
Capex per share	-0.06	-0.05	-0.04	-0.05	-0.03

CDNA Frequently Asked Questions

What is CareDx, Inc stock symbol ?

CareDx, Inc is a US stock , located in South san francisco of Ca and trading under the symbol CDNA

What is CareDx, Inc stock quote today ?

CareDx, Inc stock price is $8.2 today.

Is CareDx, Inc stock public?

Yes, CareDx, Inc is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 923.04K
Market Capitalization 441.67M
Employee 635
CEO Mr. Abhishek Jain
Headquarters South San Francisco,CA,US
IPO Date 2014-07-17
Website https://www.caredx.com

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.